Roslin Cells Achieves Investors In People Accreditation
Thursday, April 18, 2013 at 2:16PM
Roslin Cells

Edinburgh, Scotland - 16 April 2013. Roslin Cells Ltd, world leaders in the development of cell therapies and pluripotent stem cells for applications in research, drug discovery and therapy, has achieved the prestigious Investors in People Accreditation. This is the most successful framework for business improvement through people in the UK. This accolade represents a true commitment to the continuing development of our employees, and demonstrates a solid foundation of good practice which provides a challenging and aspiring work environment for the Roslin Cells team.  

Roslin Cells joins an exclusive group of UK employers eligible to use and display the sought after Investors in People logo and plaque, and enjoy its benefits.

Commenting on the award, Janet Downie, Roslin Cells’ Chief Operating Officer said, “Investors in People accreditation is a major boost to Roslin Cells, and a tribute to the focus and professionalism of our hard-working team. The positivity and dedication of our staff were highlighted by Investors in People as key strengths, which we aim to build upon as we enter the next phase of the company’s growth. We look forward to working closely with Investors in People to ensure the continuing development and improvement of our business activities.”

Peter Russian, Chief Executive of Investors in People Scotland, said “This is a fantastic achievement for Roslin Cells. I would like to congratulate the organisation and its people on their commitment to continuous improvement. Investors in People offers a flexible, practical and easy to use business improvement tool designed to help organisations and their people achieve their objectives. I hope that more organisations in the area will be encouraged to sharpen their competitive edge by choosing to work with us.”

About Roslin Cells

Roslin Cells spun out of the renowned Roslin Institute in 2006, and has 25 staff based at the Edinburgh BioQuarter. The company operates development laboratories within Nine, Edinburgh BioQuarter and the state-of-the-art, seven clean room GMP cellular therapy manufacturing facility within the Scottish Centre for Regenerative Medicine. This industry-leading facility is specifically designed for the GMP manufacture of cell therapies which are subject to the EU Advanced Therapy Medicinal Product (ATMP) regulations.

Within our portfolio we have specialised expertise in the reprogramming and expansion of induced pluripotent stem cells (iPSCs), and were the first group in Europe to derive a clinical grade human embryonic stem cell (hESC) line.

Roslin Cells achieves its goals in a robust, ethical manner compliant with current regulatory requirements. With a highly experienced and professional team, we are committed to applying the highest standards of quality and excellence across every aspect of our business.

Ends

For more information please contact Dr Jonny McMichael, New Business Manager

Phone + 44 (0) 131 658 5189; Email: jonny.mcmichael@roslincells.com

Please click here to download a pdf version of this press release

About Investors in People

Investors in People offers a practical, flexible and easy to use tool for improving business performance and competitiveness through good practice in people strategy.

An organisation that has achieved Investors in People has been successful in adopting and maintaining its three fundamental principles: Plan - developing strategies to improve the performance of the organisation, from business goals to leadership strategies; Do - implementing those strategies, taking action to improve the performance of the organisation; Review - evaluating and adjusting those strategies, measuring their impact on the performance of the organisation.

For more information on Investors in People please visit www.iipscotland.co.uk

 

Article originally appeared on Roslin Cells (http://roslincells.com/).
See website for complete article licensing information.